Breast Cancer Clinical Trials & Research at St. Joseph Health Medical Group

In the U.S., breast cancer is the second most common cancer in women after skin cancer. It can occur in both men and women. The most common type of breast cancer is ductal carcinoma, which begins in the cells of the ducts. Breast cancer can also begin in the cells of the lobules and in other tissues in the breast. Invasive breast cancer is breast cancer that has spread from where it began in the ducts or lobules to surrounding tissue.

St. Joseph Health Medical Group is currently enrolling patients for the following breast cancer clinical trials:

Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (NCI BWEL)

Treatment agent: Health education program +/- weight loss intervention
PI: Ian Anderson, MD
Study Coordinator: Camille Shaffer // Camille.Shaffer@stjoe.org // (707) 521-3809
Resources and Links: clinicaltrials.gov NCT No: NCT02750826

A Multinational, Multicenter, Randomized, Phase 3 Study of Tesetaxel plus a Reduced Dose of Capecitabine versus Capecitabine Alone in Patients with HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated with a Taxane (JIT Odonate)

Treatment agent: Tesetaxel +/- capecitabine
PI: Ian Anderson, MD
Study Coordinator: Kim Young // Kimberly.Young@stjoe.org // (707) 521-3814
Resources and Links: clinicaltrials.gov NCT No: NCT03326674

A Phase I/IIa Study of the SV-BR-1-GM Regimen in Metastatic or Locally Recurrent Breast Cancer Patients in Combination with Pembrolizumab (BriaCell Rollover)

Treatment agent: SV-BR-1-GM + Pembrolizumab
PI: Jarrod Holmes, MD
Study Coordinator: Sabine Ucik // Sabine.Ucik@stjoe.org // (707) 521-3830
Resources and Links: clinicaltrials.gov NCT No: NCT03328026

Study of Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After Induction With First-Line Chemotherapy Plus Pembrolizumab in Triple Negative Breast Cancer (TNBC) (MK- 7339-009/Keylynk-009)

Treatment agent: Olaparib + Pembrolizumab
PI: Ian Anderson, MD
Study Coordinator: Teresa
Resources and Links: clinicaltrials.gov NCT No: NCT04191135